

July 13, 2020

ERIN OKAWA
CURRICULUM VITAE

PERSONAL HISTORY:

10833 Le Conte Avenue
22-315 MDCC
Los Angeles, CA 90095
(215)407-5956
EOkawa@mednet.ucla.edu

EDUCATION:

B.A. Biology, Communication, University of Pennsylvania, 2004
M.D. Medicine, Sidney Kimmel Medical College, 2011

Pediatric Internship, Kaiser Permanente Los Angeles Medical Center, 2011-2012
Pediatric Residency, Kaiser Permanente Los Angeles Medical Center, 2012-2014
Pediatric Endocrinology Fellowship, Boston Children's Hospital, 2014-2017

LICENSURE:

CA, A124492, 2018-2020

BOARD CERTIFICATION:

Pediatrics, 111099, October 9, 2014
Pediatric Endocrinology, 1888, November 8, 2017

PROFESSIONAL EXPERIENCE:

Urgent Care Pediatrician, Harvard Vanguard, August 30, 2015- April 30, 2018
Pediatric Hospitalist, Beverly Hospital as part of Boston Children's Hospital, August 30, 2015- April 30, 2016
Attending Physician, Boston Children's Hospital, July 1, 2017- May 31 2018
Instructor in Medicine, Harvard Medical School, July 1, 2017- May 31, 2018
Attending Physician, UCLA, June 1, 2018-
Health Sciences Clinical Assistant Professor, David Geffen School of Medicine, June 1, 2018-

HONORS AND SPECIAL AWARDS:

Young Investigator's Award, Advances in Neuroblastoma Research Conference, 2006
Farley Award, Boston Children's Hospital, 2014
EndoCareers Travel Award, Endocrine Society Meeting, 2016
Outstanding Abstract Award, Endocrine Society Meeting, 2016
Von L. Meyer Travel Award, Boston Children's Hospital, 2017

PROFESSIONAL ACTIVITIES:

Medical Doctor, Camp Joslin Diabetes Camp, 2015-2017
Co-Chair, Joslin Fellows Council, 2017-2018
Member, Physician's Society, Long Beach Memorial Hospital and Miller Children's Hospital, 2018-
Member, American Medical Association, 2019-2020

Medical Doctor, Camp Conrad Chinook, 2019-

LECTURES AND PRESENTATIONS:

Expression profiling and mutation analysis of candidate tumor suppressor genes on 1p36.3, Advances in Neuroblastoma Research Conference, Los Angeles, CA, 2006
Expression and sequence analysis of candidates for the 1p36.31 tumor suppressor gene, Advances in Neuroblastoma Research Conference, Chiba, Japan, 2008
Cushing syndrome in a 4-month old boy: an unusual presentation of an uncommon disorder, Department of Endocrinology, Brigham and Women's Hospital and Division of Endocrinology, Boston Children's Hospital Grand Rounds, Boston, MA, 2015
Hyperinsulinism; Harbor-UCLA Translational Endocrinology Conference, Torrance, CA 2019

RESEARCH PAPERS

RESEARCH PAPERS (PEER REVIEWED)

A. RESEARCH PAPERS - PEER REVIEWED

1. White PS, Thompson PM, Gotoh T, **Okawa ER**, Igarashi J, Kok M, Winter C, Gregory SG, Hogarty MD, Maris JM, Brodeur GM. Definition and characterization of a region of 1p36.6 consistently deleted in neuroblastoma. *Oncogene*, 2005, 24(16):2684-94. *Performed genotyping and loss of heterozygosity analysis of neuroblastoma tumor samples; completed transcriptional expression profiles of genes in the smallest region of deletion in a panel of normal tissues.*
2. Wang Q, Diskin S, Rappaport E, Attiyeh E, Mosse Y, Shue D, Seiser E, Jagannathan J, Shusterman S, Bansal M, Khazi D, Winter C, **Okawa E**, Grant G, Cnaan A, Zhao H, Cheung N, Gerald W, London W, Matthay K, Brodeur GM, Maris JM. Integrative genomics identifies distinct molecular classes of neuroblastoma and shows that multiple genes are targeted by regional alterations in DNA copy number. *Cancer Research*, 2006, 66(12):6050-62. *Performed quantitative RT-PCR validation of genes differentially expressed in the microarray.*
3. **Okawa ER**, Gotoh T, Igarashi J, Fujita T, Manne J, Silverman KA, Mosse Y, White PS, Brodeur GM. Expression and sequence analysis of candidates for the 1p36.31 tumor suppressor gene deleted in neuroblastomas. *Oncogene*, 2008, 27(6):803-10.
4. Fujita T, Igarashi J, **Okawa ER**, Gotoh T, Manne J, Kim J, Zhao H, Pawel B, Maris JM, White PS, Brodeur GM. *CHD5*, a tumor suppressor gene deleted from 1p36.31 in neuroblastomas. *Journal of the National Cancer Institute*, 2008, 100(13):940-9. *Analyzed CHD5 expression via quantitative RT-PCR in neuroblastoma cell lines.*
5. Naraparaju K, Kolla V, Zhuang T, Higashi M, Iyer R, Kolla S, **Okawa ER**, Blobel GA, Brodeur GM. Role of microRNAs in epigenetic silencing of the *CHD5* tumor suppressor. *Oncotarget*, 2016, 7(13):15977-85.

July 13, 2020

Performed luciferase reporter assays to verify the binding of various microRNAs that bind 3'-UTR of CHD5 mRNA.

6. Shirakawa J, Fernandez M, Takatani T, El Ouaamari A, Jungtrakoon P, **Okawa ER**, Zhang W, Yi P, Doria A, Kulkarni RN. Insulin signaling regulates the FoxM1/PLK1/CEN-PA pathway to promote beta cell proliferation. *Cell Metabolism*, 2017, 4;25(4):868-882.e5.
Assisted with animal studies.
7. Weng CH, **Okawa ER**, Roberts MB, Park SK, Umbricht CB, Manson JE, Eaton CB. Breast cancer risk in postmenopausal women with medical history of thyroid disorder in the Women's Health Initiative. *Thyroid*, 2020, 30(4): 519-530.
Assisted with manuscript writing, editing. Assisted with interpretation of data.

B. RESEARCH PAPERS - PEER REVIEWED (IN PRESS) None

C. RESEARCH PAPERS - PEER REVIEWED (SUBMITTED)

1. Okawa ER, Gupta MK, Kahraman S, Goli P, Sakaguchi M, Hu J, Duan K, Slipp B, Lennerz JK, Kulkarni RN. Differential roles of insulin and IGF-1 receptors during embryonic lineage development. [Molecular Metabolism]

RESEARCH PAPERS (NON- PEER REVIEWED)

D. RESEARCH PAPERS - NON-PEER REVIEWED None

E. RESEARCH PAPERS - NON-PEER REVIEWED (IN PRESS) None

F. RESEARCH PAPERS - NON-PEER REVIEWED (SUBMITTED) None

CASE REPORTS None

CHAPTERS None

LETTERS TO THE EDITOR None

REVIEWS

1. **Okawa ER**, Grant FD, Smith JR. Pediatric Graves' disease: decisions regarding therapy. *Current Opinion in Pediatrics*, 2015, 27(4):442-7.
2. Kahraman S, **Okawa ER**, Kulkarni RN. Is transforming stem cells to pancreatic beta cells the holy grail for type 2 diabetes? *Current Diabetes Reports*, 2016, 16(8):70.
Co-first author

EDITORIALS None

PAPERS IN PREPARATION (RESEARCH COMPLETED) None

ABSTRACTS

1. **Okawa ER**, Astley C, Whittemore K, Laffel L, Huang S. An unusual case of suppurative thyroiditis in a child. International Thyroid Congress, Orlando, FL, October 2015.
2. **Okawa ER**, Gardner R, Feltmate C, Hirsch MS, Craig JW, Chan YM. An unusual case of secondary amenorrhea in an adolescent. Endocrine Society Meeting, Boston, MA, April 2016.
Invited to compete in the Endocrine Society's Presidential Poster Competition for a first-authored top-scoring abstract for presentation at the Annual Meeting & Expo
3. **Okawa ER**, Perez-Atayde A, Thaker VV. Congenital mesoblastic nephroma: not so benign? Endocrine Society Meeting, Boston, MA, April 2016.
4. **Okawa ER**, Ma N, Wolfsdorf JI. A challenging case of persistent hyperinsulinemic hypoglycemia in the neonate. Congenital Hypoglycemia Disorders: Hyperinsulinism and GSD Meeting, Philadelphia, PA, April 2016.
5. **Okawa ER**, Smith JR. Remission of Type 1 Diabetes after Radioiodine Ablation for Graves' Disease: A Novel Case Report. American Thyroid Association, Denver, CO, September 2016.
6. **Okawa ER**, Gupta MK, Sakaguchi S, Kulkarni RN. Studies in insulin receptor/Insulin-like growth factor-1 receptor double knock-out cells imply a role for insulin-like growth factor-2 receptor in pluripotency and differentiation of stem cells. American Diabetes Association, San Diego, CA, June 2017.
Chosen for a moderated poster discussion.
7. **Okawa ER**, Gupta MK, Hu J, Duan K, Slipp B, Kulkarni RN. The Role of Insulin and IGF-I Receptor Signaling in the Pluripotency, Differentiation and Maintenance of Stem Cells. American Diabetes Association, Orlando, FL, June 2018.